OnKure grants 110,000 stock options to CSO
Hartley Dylan reported acquisition or exercise transactions in this Form 4 filing.
Rhea-AI Filing Summary
Hartley Dylan reported acquisition or exercise transactions in this Form 4 filing.
OnKure Therapeutics, Inc. reported that Chief Scientific Officer Dylan Hartley received a grant of 110,000 employee stock options to buy Class A Common Stock at $4.07 per share. These options expire on March 31, 2036 and function as equity-based compensation rather than an open-market share purchase.
According to the vesting terms, 1/48th of the options will vest on May 1, 2026 and then monthly thereafter, as long as Hartley continues as a service provider. After this grant, Hartley directly holds 110,000 options covering an equal number of Class A Common shares.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Employee Stock Option (right to buy) | 110,000 | $0.00 | $0.00 |
Footnotes (1)
- F1. 1/48th of the shares subject to the option shall vest on May 1, 2026 and each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
Key Figures
Key Terms
Employee Stock Option financial
Class A Common Stock financial
exercise price financial
vesting financial
derivative financial
FAQ
What insider transaction did OnKure Therapeutics (OKUR) report for Dylan Hartley?
What are the key terms of Dylan Hartley’s 110,000 OnKure stock options?
How do Dylan Hartley’s OnKure (OKUR) stock options vest over time?
When do Dylan Hartley’s OnKure stock options expire if unexercised?
AI-generated analysis. How Rhea-AI works. Not financial advice.